AbbVie is a global biopharmaceutical company established in 2013 as a spin-off from Abbott Laboratories. Headquartered in Tokyo, Japan, AbbVie focuses on discovering and delivering innovative medicines that address complex health issues and enhance patients' lives. The company employs over 14,000 scientists and staff across 17 countries, with a significant research and development presence in Tokyo, where it supports clinical development and regulatory approvals tailored to Japanese patients.

AbbVie's portfolio includes a wide range of pharmaceutical products targeting serious diseases, with therapeutic areas such as oncology, immunology, neuroscience, and virology. Notable products include IMBRUVICA and VENCLEXTA/VENCLYXTO, which have received approvals in major markets. The company actively pursues partnerships and collaborations, particularly in Asia, to foster innovation and accelerate the development of new therapies. AbbVie is committed to making its medicines accessible to patients worldwide, ensuring a patient-centered approach in all its initiatives.